Effect of Costimulatory Blockade With Abatacept After Ustekinumab Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: The PAUSE Randomized Clinical Trial

IMPORTANCE: Psoriasis relapse may involve compensatory T-cell activation pathways in the presence of CD28-CD80/CD86 blockade with abatacept. OBJECTIVE: To determine whether costimulatory signaling blockade with abatacept prevents psoriasis relapse after ustekinumab withdrawal. DESIGN, SETTING, AND P...

Descripción completa

Detalles Bibliográficos
Autores principales: Harris, Kristina M., Smilek, Dawn E., Byron, Margie, Lim, Noha, Barry, William T., McNamara, James, Garcet, Sandra, Konrad, Robert J., Stengelin, Martin, Bathala, Pradeepthi, Korman, Neil J., Feldman, Steven R., Boh, Erin E., Barber, Kirk, Laumann, Anne E., Helfrich, Yolanda Rosi, Krueger, Gerald G., Sofen, Howard, Bissonnette, Robert, Krueger, James G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515260/
https://www.ncbi.nlm.nih.gov/pubmed/34643650
http://dx.doi.org/10.1001/jamadermatol.2021.3492

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515260/
https://www.ncbi.nlm.nih.gov/pubmed/34643650
http://dx.doi.org/10.1001/jamadermatol.2021.3492

Ejemplares similares